Actos Franchise Drives Takeda's Pharmaceutical Sales Growth
This article was originally published in PharmAsia News
Executive Summary
Higher sales of Actos (pioglitazone) products were the prime driver behind a 7.7 percent increase in Takeda's pharmaceuticals segment for the nine months ending Dec. 31, 2007, compared with the same period in 2006, the company reported Jan. 31.
You may also be interested in...
Takeda Cholesterol Drug Filing Set Back Due To Liver Enzyme Data
A cholesterol drug Takeda had planned to file in the first quarter of 2008 has been delayed after elevated transaminase levels were seen in some patients taking a higher dose of the product in clinical trials, the Japanese firm announced Oct. 29. FDA has requested additional clinical trial data on TAK-475 (lapaquistat), a squalene synthase inhibitor
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).